# Everolimus in de Novo Heart Transplant Recipients

> **NCT01017029** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 182 (actual)

## Conditions studied

- Cardiac Transplantation

## Interventions

- **DRUG:** Everolimus
- **DRUG:** Mycophenolate mofetil + Everolimus

## Key facts

- **NCT ID:** NCT01017029
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 182 (ACTUAL)
- **Last updated:** 2015-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01017029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01017029, "Everolimus in de Novo Heart Transplant Recipients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01017029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*